Nuvectis Pharma to Participate in Maxim Growth Summit 2026
News related to:Nuvectis Pharma, Inc · 1 min read
Fort Lee, NJ, Oct. 09, 2026 /CourierPR/ -- Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for complement-related conditions and oncology, will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026, in New York.
The company’s senior management will present at the event, which will feature a webcast of the panel discussion available on Nuvectis’ website at www.nuvectis.com.
Nuvectis Pharma’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor currently in development for the treatment of complement-mediated diseases. The company is also advancing NXP900 and NXP200, oncology drug candidates designed to treat advanced cancers. NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, with best-in-class potential. NXP900, an oral small molecule inhibitor of the SRC family kinases, including SRC and YES1, is also in development.
Ciprocopan, the company’s lead drug candidate, is a once-a-day Factor B inhibitor with best-in-class potential. Recently, it was approved in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) patients who have not been previously treated with complement inhibitors.
NXP200, with its unique mechanism of action, aims to address unmet needs in the treatment of advanced cancers. The drug candidate is designed to overcome resistance and break the paradox of BRAF inhibitors, making it a promising option for patients with specific mutations.
NXP900, on the other hand, targets a family of kinases involved in various cellular processes, including cell growth and survival. The company believes that this drug candidate could offer a new therapeutic approach for a range of solid tumors.
Nuvectis Pharma’s participation in the Maxim Growth Summit 2026 underscores the company’s commitment to advancing its pipeline and bringing innovative therapies to patients suffering from complement-related conditions and advanced cancers. The event will provide an opportunity for the company to share its progress and engage with industry leaders and investors.